Sign Out
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
VaxigripTetra NH/VaxigripTetra SH should under no circumstances be administered intravascularly.
As with other vaccines administered intramuscularly, the vaccine should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.
VaxigripTetra NH/VaxigripTetra SH is intended to provide protection against those strains of influenza virus from which the vaccine is prepared.
As with any vaccine, vaccination with VaxigripTetra NH/VaxigripTetra SH may not protect all vaccinees.
Regarding passive protection, not all infants younger than 6 months of age born to women vaccinated during pregnancy will be protected (see Pharmacology: Pharmacodynamics under Actions).
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.
Interference with serological testing: See Interactions.
Effects on ability to drive and use machines: VaxigripTetra NH/VaxigripTetra SH has no or negligible influence on the ability to drive and use machines.
